473 results on '"Schendel Dolores J"'
Search Results
2. Defining the critical hurdles in cancer immunotherapy
3. Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission
4. Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentation
5. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response
6. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70
7. A role for MCP-1/CCR2 in interstitial lung disease in children
8. A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma
9. Evolution by innovation as a driving force to improve TCR-T therapies
10. Abstract 4057: T cells co-expressing a highly potent NY-ESO-1-specific TCR and a chimeric PD1-41BB co-stimulatory switch receptor show a favorable polyfunctional profile for the treatment of solid tumors
11. methods from Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
12. Data from Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
13. Data from T-Cell Receptor Gene–Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy
14. Supplementary Data from T-Cell Receptor Gene–Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy
15. The ABCs of T Cell Receptor Gene Therapy
16. Cell-Based Vaccines for Renal Cell Carcinoma
17. Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCL
18. TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo
19. Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer
20. Recruitment of MHC-Restricted Cytotoxic T Lymphocytes Specific for Renal Cell Carcinoma to the Tumor In Situ
21. Long‐term first‐in‐man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high‐risk prostate cancer after radical prostatectomy
22. New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia
23. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells
24. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity
25. High Immune Response Rates and Decreased Frequencies of Regulatory T Cells in Metastatic Renal Cell Carcinoma Patients after Tumor Cell Vaccination
26. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors
27. Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma
28. Long Term Follow up of a “Fast-DC” Immunotherapy Against WT-1 and PRAME As a Post-Remission Strategy for AML
29. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy
30. Effects of galactooligosaccharide and long-chain fructooligosaccharide supplementation during pregnancy on maternal and neonatal microbiota and immunity—a randomized, double-blind, placebo-controlled study
31. Quantitative and functional impairment of pulmonary CD4 +CD25 hi regulatory T cells in pediatric asthma
32. Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells
33. Expitope 2.0: a tool to assess immunotherapeutic antigens for their potential cross-reactivity against naturally expressed proteins in human tissues
34. PRAME mRNA Expression in AML/MDS and HLA Genotype Analysis: Impact on Population Coverage and Design of TCR-Based Immunotherapies
35. A WT-1 and PRAME "Fast-DC" Immunotherapy As a Potential Post-Remission Strategy for AML
36. T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity.
37. Long‐term first‐in‐man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high‐risk prostate cancer after radical prostatectomy.
38. Association between levels of Toll-like receptors 2 and 4 and CD14 mRNA and allergy in pregnant women and their offspring
39. Adoptive tumor therapy with T lymphocytes enriched through an IFN-[gamma] capture assay
40. Abstract 3231: The chimeric co-stimulatory receptor PD1-41BB enhances the function of T cell receptor (TCR)-modified T cells targeting solid tumors
41. Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial
42. Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma – a case report
43. Machine Learning for Cancer Immunotherapies Based on Epitope Recognition by T Cell Receptors
44. Current use of room disinfectants and allergic symptoms at the age of 4 years
45. HLA-C revisited: Ten Years of Change
46. IMMUNE MONITORING OF AN ALLOGENIC GENETICALLY- MODIFIED TUMOR CELL VACCINE (RCC-26/CD80/IL-2) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: 1200
47. Decreased cord blood IL-4, IL-13, and CCR4 and increased TGF-β levels after fish oil supplementation of pregnant women
48. Dominance of CD4+ Lymphocytic Infiltrates With Disturbed Effector Cell Characteristics in the Tumor Microenvironment of Prostate Carcinoma
49. Quantitative and functional impairment of pulmonary CD4+CD25hi regulatory T cells in pediatric asthma
50. Machine Learning for Cancer Immunotherapies Based on Epitope Recognition by T Cell Receptors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.